AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

Shares of Revance Therapeutics surged more than 16% on Monday morning, reaching over a month’s high, leading to a jump in retail chatter on Stocktwits. The surge followed a proposal from ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO. Learn why RVNC shares trade close to an all-time low today. Skip to content.

Crown Labs, which agreed to acquire Revance Therapeutics for $6.66 a share in cash last month, was expected to start a tender offer by a Friday deadline, according to an 8-K filing from Aug. 28 ...

Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge ...

Revance Therapeutics, Inc. reported its Q4 and FY 23 earnings yesterday, February 28th - its stock price has been soaring as a result. The company is guiding for ~$280m of revenues in 2024 and ...

(RTTNews) - Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of ...

Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical ...